Zantac / Ranitidine (NDMA Cancer) Lawsuit in Iowa

NDMA stands for N-nitrosodimethylamine, a chemical classified as a probable human carcinogen by the International Agency for Research on Cancer (IARC) and the U.S. Environmental Protection Agency (EPA). NDMA is a potent carcinogen that has been shown to cause liver, lung, kidney, and bladder cancer in animal studies, and epidemiological research in humans has associated chronic NDMA exposure with elevated cancer risk. The FDA sets an acceptable daily intake limit of 96 nanograms for NDMA — a level designed to ensure that lifetime exposure carries negligible additional cancer risk. Independent testing found Zantac (ranitidine) tablets containing NDMA at levels over 300,000 nanograms — more than 3,000 times the FDA limit — and demonstrated that NDMA is generated from the ranitidine molecule itself during metabolism in the human body.

All ranitidine-containing products are potentially implicated, including: branded Zantac in all dosages and formulations (Sanofi, formerly GSK and Pfizer); generic ranitidine tablets and capsules from major manufacturers including Boehringer Ingelheim and numerous other generic producers; store-brand ranitidine sold by CVS, Walgreens, Walmart, Target, and other retailers; and prescription-strength ranitidine in any dosage form. The NDMA problem is inherent to the ranitidine molecule itself — it is not limited to a specific batch, lot, or manufacturer. Any ranitidine product taken over a sustained period (generally 1 or more years) qualifies for purposes of establishing exposure in litigation.

The cancers most widely accepted in Zantac state court litigation are: bladder cancer (the most strongly linked, as NDMA is excreted through the urinary tract), stomach cancer, colorectal cancer, and esophageal cancer. Breast cancer and prostate cancer have also been pursued in litigation and are accepted by many plaintiff's firms as qualifying cancers. Liver cancer and kidney cancer have been raised in some cases. The strength of scientific support varies by cancer type — bladder and gastrointestinal cancers have the most robust epidemiological backing. An attorney can evaluate your specific cancer type, your ranitidine use history, and the current state of litigation acceptance to advise whether your claim has strong prospects.

Most Zantac litigation attorneys require a minimum of one year of regular use — either prescription ranitidine or OTC Zantac — to establish meaningful NDMA exposure sufficient for litigation. This threshold is based on pharmacokinetic and epidemiological evidence showing that cancer risk is associated with sustained, cumulative NDMA exposure rather than short-term or occasional use. Use does not need to be continuous — patients who used ranitidine regularly over a multi-year period with some gaps may still qualify. Both daily use and regular episodic use (e.g., weekly for chronic heartburn management) can satisfy the use requirement. Pharmacy records, insurance prescription histories, and physician records documenting ranitidine prescriptions or OTC use recommendations are the best evidence of use.

Yes. On April 1, 2020, the FDA requested that all manufacturers of prescription and OTC ranitidine products immediately withdraw those products from the U.S. market. While technically a market withdrawal request rather than a mandatory recall, all major manufacturers complied. The FDA's basis was that NDMA levels in ranitidine products increase over time and under typical storage conditions, reaching levels that are unacceptably high for human consumption. The FDA also stated that it could not identify a manufacturing approach that would reliably prevent NDMA formation in ranitidine products. This April 2020 action effectively ended the availability of ranitidine in the U.S. market and is a key date in Zantac litigation for statute of limitations purposes.

The federal multidistrict litigation (MDL) against Zantac manufacturers was consolidated in the Southern District of Florida before Judge Robin L. Rosenberg. In November 2022, Judge Rosenberg issued a ruling granting defendants' Daubert motions, which excluded all of the plaintiffs' general causation expert witnesses. The court found that plaintiffs' experts used scientifically unreliable methodologies to establish that ranitidine causes cancer. Without admissible causation experts, plaintiffs could not prove their cases, and the MDL was effectively dismissed. The Eleventh Circuit Court of Appeals affirmed the dismissal, and the U.S. Supreme Court declined review. The federal MDL is closed. However, this ruling applies only to federal court and does not bind or affect state court claims, which proceed under their own evidentiary rules.

Yes — state court litigation is active in 2026. The federal MDL dismissal in November 2022 was a significant setback in federal court only. State courts apply their own expert evidentiary standards, and Zantac litigation continues actively in Delaware Superior Court and California state courts. Plaintiffs' attorneys have refined their expert presentations since the federal Daubert ruling. Whether you can still file depends primarily on your state's statute of limitations and whether your claim falls within that window under the discovery rule. Claimants with cancer diagnoses from 2021 onward and documented Zantac use of 1+ years should consult a pharmaceutical litigation attorney promptly to evaluate their specific deadline. Do not assume the federal MDL outcome forecloses your options.

Delaware Superior Court is the most active state court venue for Zantac litigation in 2026, with thousands of consolidated cases proceeding under coordinated case management. California state courts also have active Zantac litigation dockets. Additionally, individual state court filings have been pursued in Texas, Florida, Illinois, New Jersey, Pennsylvania, and other states with significant plaintiff populations. Delaware is often favored because it uses the Frye evidentiary standard for expert testimony — different from the federal Daubert standard that led to the MDL dismissal — and because major pharmaceutical defendants are incorporated in Delaware, providing favorable jurisdiction for personal jurisdiction purposes.

The key evidence for a Zantac cancer claim consists of two categories: (1) Proof of ranitidine use — pharmacy prescription records (obtainable from your pharmacy with a HIPAA authorization), insurance claims showing ranitidine prescriptions, receipts or store loyalty card records for OTC purchases, and physician records documenting ranitidine recommendations or prescriptions; and (2) Medical records establishing cancer diagnosis — pathology reports confirming cancer type and staging, oncology records, treatment records, and, if applicable, death certificate and autopsy report for wrongful death claims. You do not need to save old Zantac bottles or packaging, though any physical evidence of use is helpful. Your attorney will assist in obtaining pharmacy records, which are often the most reliable proof of long-term use.

Claimants in Zantac litigation can seek both economic and non-economic damages. Economic damages include: all past and future medical expenses related to cancer diagnosis and treatment (surgery, chemotherapy, radiation, immunotherapy, follow-up care); lost wages and diminished earning capacity caused by cancer treatment and disability; and out-of-pocket costs for medications, transportation, and home care. Non-economic damages include: pain and suffering from cancer diagnosis and treatment; emotional distress and mental anguish; loss of enjoyment of life; and disfigurement or permanent impairment. Wrongful death claims add funeral and burial expenses, loss of financial support for dependents, and loss of companionship. Punitive damages may be available against manufacturers who knew about the NDMA risk and failed to warn consumers.

NDMA causes cancer through a process called DNA alkylation. When NDMA is metabolized in the body — primarily in the liver by the cytochrome P450 enzyme system — it is converted to reactive intermediates (methyl diazonium ions) that form covalent bonds with DNA nucleotide bases, creating DNA adducts. These DNA adducts, particularly O6-methylguanine, are mutagenic — they cause misreading of the DNA sequence during cell replication. If the repair mechanisms that normally correct these mutations are overwhelmed or impaired, the mutations accumulate and can trigger uncontrolled cell growth, leading to tumor formation. Chronic, repeated exposure to NDMA — as occurs with daily ranitidine use over years — results in sustained DNA damage that progressively overwhelms DNA repair capacity, increasing cancer risk over time. This mechanism is well-established in toxicology and is the basis for NDMA's IARC Group 2A carcinogen classification.

The statute of limitations for Zantac cancer claims varies by state but is typically 2 to 3 years from the date of cancer diagnosis — or from the date you knew or reasonably should have known that your Zantac use may have caused your cancer (the discovery rule). The FDA's April 2020 market withdrawal placed the public on notice of the NDMA-ranitidine connection, meaning that in many states, limitations periods for pre-2020 diagnoses began running in April 2020. A 2-year deadline would have expired April 2022; a 3-year deadline would have expired April 2023. However, claimants diagnosed with cancer after April 2020, or those who can demonstrate delayed discovery, may still have timely claims in 2026. Delaware (2 years from diagnosis discovery) and California (2 years under CCP § 335.1 with discovery rule) are the most active state court venues. An attorney can evaluate the specific deadline applicable to your diagnosis and state.